tetano
Editor, Senior Moderator
Vaccine
Volume 30, Issue 49, 19 November 2012, Pages 7067?7071
Cover image
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults
Allan Bybeck Nielsena, Corresponding author contact information, E-mail the corresponding author,
Henriette Schj?nning Nielsenb,
Lars Nielsenb,
S?ren Thyboc,
Gitte Kronborga
a Department for Infectious Diseases, Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark
b Department of Virology, Statens Serum Institute, National Institute for Health Data and Disease Control, Copenhagen, Denmark
c Department for Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
http://dx.doi.org/10.1016/j.vaccine.2012.09.052, How to Cite or Link Using DOI
Permissions & Reprints
View full text
Purchase $31.50
Abstract
Introduction
Continued research is needed to evaluate and improve the immunogenicity of influenza vaccines in HIV infected patients. We aimed to determine the antibody responses after one or two doses of the AS03-adjuvanted pandemic influenza A (H1N1) vaccine in HIV infected patients.
Method
Following the influenza season 2009/2010, 219 HIV infected patients were included and divided into three groups depending on whether they received none (n = 60), one (n = 31) or two (n = 128) doses of pandemic influenza A (H1N1) vaccine. At inclusion, antibody titers for all patients were analyzed and compared to pre-pandemic antibody titers analyzed from serum samples in a local storage facility.
Results
4?9 months after a single immunization, we found a seroprotection rate of 77.4% and seroconversion rate of 67.7%. After two immunizations the rates increased significantly to seroprotection rate of 97.7% and seroconversion rate of 86.7%.
Conclusion
A single dose of AS03-adjuvanted pandemic influenza A (H1N1) vaccine created an adequate immune response in HIV infected patients lasting as long as 4?9 months. Two doses improved the immunogenicity further.
Highlights
► One dose of adjuvanted vaccine creates sufficient response in HIV infected patients. ► Two doses improve immunogenicity further. ► Response evaluated 4?9 months after immunization.
http://www.sciencedirect.com/science/article/pii/S0264410X12013722
Volume 30, Issue 49, 19 November 2012, Pages 7067?7071
Cover image
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults
Allan Bybeck Nielsena, Corresponding author contact information, E-mail the corresponding author,
Henriette Schj?nning Nielsenb,
Lars Nielsenb,
S?ren Thyboc,
Gitte Kronborga
a Department for Infectious Diseases, Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark
b Department of Virology, Statens Serum Institute, National Institute for Health Data and Disease Control, Copenhagen, Denmark
c Department for Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
http://dx.doi.org/10.1016/j.vaccine.2012.09.052, How to Cite or Link Using DOI
Permissions & Reprints
View full text
Purchase $31.50
Abstract
Introduction
Continued research is needed to evaluate and improve the immunogenicity of influenza vaccines in HIV infected patients. We aimed to determine the antibody responses after one or two doses of the AS03-adjuvanted pandemic influenza A (H1N1) vaccine in HIV infected patients.
Method
Following the influenza season 2009/2010, 219 HIV infected patients were included and divided into three groups depending on whether they received none (n = 60), one (n = 31) or two (n = 128) doses of pandemic influenza A (H1N1) vaccine. At inclusion, antibody titers for all patients were analyzed and compared to pre-pandemic antibody titers analyzed from serum samples in a local storage facility.
Results
4?9 months after a single immunization, we found a seroprotection rate of 77.4% and seroconversion rate of 67.7%. After two immunizations the rates increased significantly to seroprotection rate of 97.7% and seroconversion rate of 86.7%.
Conclusion
A single dose of AS03-adjuvanted pandemic influenza A (H1N1) vaccine created an adequate immune response in HIV infected patients lasting as long as 4?9 months. Two doses improved the immunogenicity further.
Highlights
► One dose of adjuvanted vaccine creates sufficient response in HIV infected patients. ► Two doses improve immunogenicity further. ► Response evaluated 4?9 months after immunization.
http://www.sciencedirect.com/science/article/pii/S0264410X12013722